The placebo - its spooky power, its basis and the ethics of using it: @lizabio explores recent research #PLOSBiology https://t.co/Jf4NbR5pJy pic.twitter.com/aIYr8MWAzA
— PLOS Biology (@PLOSBiology) February 22, 2017
A review @NEJM on (and by) the @US_FDA drug approval process https://t.co/kKpY2InigB
— Eric Topol (@EricTopol) February 15, 2017
and some concerns of mine: https://t.co/Vqm7OUcv8w pic.twitter.com/9M7t6xq7tn
Great free series of reviews and articles in special issue of Cell.
— Dan Marks (@Festivus159) February 9, 2017
Cancer: The Road Ahead.https://t.co/trRIkxVbwg pic.twitter.com/rjhEzFpw8t
We found @SenTedCruz proposed reciprocal approval legislation would benefit few patients (w/ rare dz), increase harm https://t.co/PRaRKUANiO pic.twitter.com/qzwpdl8hPU
— Joseph Ross (@jsross119) February 8, 2017
John Jenkins, ex-Director of FDA Office of New Drugs, discusses approvals standards and more https://t.co/UTpuUqtfJq https://t.co/WMhDSIUdbV
— Nature Rev Drug Disc (@NatRevDrugDisc) February 2, 2017
Very nice review from Ionis' CEO Stan Crooke => Molecular Mechanisms of Antisense Oligonucleotides https://t.co/nDqoprl3rd #bbv pic.twitter.com/857JfQPWPD
— Paul Burke (@ontargt) January 16, 2017
Important: @ScienceMagazine piece shares progress in reproducing BET Bromodomain, other cancer studies https://t.co/SxhHp0l70a 1/2
— Jay Bradner, M.D. (@jaybradner) January 19, 2017
Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis — NEJM $INCY https://t.co/Ay130nhWGQ
— Biotech Hack (@BiotechHack) February 15, 2017
RSS Feed
